Randox Technology Offers Multiple Cardiac Tests within Minutes
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Randox Laboratories have launched a new Biochip Analyzer that will save cardiac patients lives by providing immediate diagnosis at the point of care.
The Randox Evidence MultiStat is a new desktop analyzer which offers up to 8 cardiac results within just 20 minutes. This new technology ensures the commercial laboratory analyzer within the A & E department delivering significant benefits for those patients with chest pains by identifying risk and enabling accurate clinical decisions.
With some blood biomarkers only detectable for 6 hours after a heart attack, patients presenting with early symptoms are often missed. The Evidence MultiStat will ultimately save patient lives by giving accurate and timely diagnosis when time is at a premium.
The Evidence MultiStat is based upon the award winning Biochip technology from Randox and utilizes the precision and accuracy of the commercially available lab based Evidence analyzer giving the Evidence MultiStat distinct advantages over other lower quality rapid devices currently in the market.
The Evidence MultiStat also offers an array for drugs of abuse with arrays for stroke, metabolic syndrome, cancer, fertility disorders, thyroid disorders, synthetic steroids and additional drugs of abuse currently in development. The system is suitable for a variety of point of patient environments including emergency departments, cardiac units, doctor surgeries, forensic units, rehab units and employee drug screening centres.
The technology offers fully automated pipetting, incubation, washing, imaging and report generation ensuring that the MultiStat can be used by non technical staff. User friendly touch screen Windows ® based software also ensures little or no training is required.
The Randox Evidence MultiStat is a new desktop analyzer which offers up to 8 cardiac results within just 20 minutes. This new technology ensures the commercial laboratory analyzer within the A & E department delivering significant benefits for those patients with chest pains by identifying risk and enabling accurate clinical decisions.
With some blood biomarkers only detectable for 6 hours after a heart attack, patients presenting with early symptoms are often missed. The Evidence MultiStat will ultimately save patient lives by giving accurate and timely diagnosis when time is at a premium.
The Evidence MultiStat is based upon the award winning Biochip technology from Randox and utilizes the precision and accuracy of the commercially available lab based Evidence analyzer giving the Evidence MultiStat distinct advantages over other lower quality rapid devices currently in the market.
The Evidence MultiStat also offers an array for drugs of abuse with arrays for stroke, metabolic syndrome, cancer, fertility disorders, thyroid disorders, synthetic steroids and additional drugs of abuse currently in development. The system is suitable for a variety of point of patient environments including emergency departments, cardiac units, doctor surgeries, forensic units, rehab units and employee drug screening centres.
The technology offers fully automated pipetting, incubation, washing, imaging and report generation ensuring that the MultiStat can be used by non technical staff. User friendly touch screen Windows ® based software also ensures little or no training is required.
